Akebia Therapeutics Q3 2026 Earnings Date & Estimates

Akebia Therapeutics (NASDAQ:AKBA) is a biopharmaceutical company focused on developing and commercializing treatments for patients with kidney disease and related complications. The company’s portfolio centers on therapies for anemia associated with chronic kidney disease (CKD), a condition that can result from reduced kidney function and insufficient production of erythropoietin.

Akebia’s primary product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In the United States, Vafseo is approved to treat anemia due to CKD in adults who have been receiving dialysis for at least three months. The product is designed to stimulate the body’s natural response to low oxygen levels and support red blood cell production.

The company also markets Auryxia (ferric citrate), which is approved in the United States for controlling serum phosphorus levels in adults with CKD on dialysis and for treating iron-deficiency anemia in certain adults with non-dialysis-dependent CKD. Akebia gained Auryxia through its combination with Keryx Biopharmaceuticals in 2018. The company is headquartered in Cambridge, Massachusetts, and serves patients primarily through its commercial operations in the United States, while pursuing international opportunities through partnerships and licensing arrangements.

John P. Butler has served as Akebia’s president and chief executive officer since 2016. The company’s operations and research activities remain focused on renal medicine, including the development and commercialization of therapies intended to address significant unmet needs among people with CKD.